Evidence map›Paper›PMID 28693790›Full record

ReviewCritical reviews in oncology/hematology2017

Application of metabolomics in sarcoma: From biomarkers to therapeutic targets.

Li Min, Edwin Choy, Chongqi Tu, Francis Hornicek, Zhenfeng Duan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Critical reviews in oncology/hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping.International journal of molecular sciences · 2022
    Review
  4. Diagnostic Value ofACS omega · 2022
    Article
  5. Review
  6. Review
  7. The free amino acid profiles and metabolic biomarkers of predicting the chemotherapeutic response in advanced sarcoma patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Li MinSarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA; Department of Orthopedics, West China Hospital, Sichuan University, 37 Guoxue Road, Chengdu, Sichuan, 610041, China.
Edwin ChoySarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA.
Chongqi TuDepartment of Orthopedics, West China Hospital, Sichuan University, 37 Guoxue Road, Chengdu, Sichuan, 610041, China.
Francis HornicekSarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA.
Zhenfeng DuanSarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Jackson 1115, Boston, MA 02114, USA. Electronic address: zduan@mgh.harvard.edu.

Funding

COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCEU01CA151452 · NCI · NORTHEASTERN UNIVERSITY · PI AMIJI, MANSOOR M., DUAN, ZHENFENG · 2010 to 2014
$2.1M
NCI NIH HHS U01 CA151452
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID28693790
PMCPMC5527996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.